Investment Thesis
Enveric faces severe operational distress with negative revenue, persistent operating losses of $8.8M, and annual cash burn of $8.1M against only $4.7M in cash reserves—implying less than 7 months of runway. The pharmaceutical company's inability to generate positive revenue combined with corrupted margin data signals potential accounting irregularities and fundamental business dysfunction.
Strengths
- Low leverage with debt-to-equity of 0.18x provides financial flexibility
- Current ratio of 5.38x indicates adequate short-term liquidity relative to liabilities
- Diluted EPS improved 84.1% YoY, suggesting some reduction in losses (though from deeply negative base)
Risks
- Negative revenue ($-106M) indicates severe business contraction, product returns, or accounting anomalies
- Cash burn rate of $8.1M annually against $4.7M cash reserves leaves <7 months of operational runway
- Profitability metrics show extreme data quality issues (margins >5M% impossible) suggesting potential accounting or reporting problems
- No insider trading activity in 90 days may indicate loss of investor confidence
- Minimal capex spend suggests collapsed operations or restructuring in biotech sector
Key Metrics to Watch
- Quarterly revenue trends and path to positive revenue
- Monthly cash burn rate and cash runway extension
- Reconciliation of reported margin data anomalies and accounting corrections
Financial Metrics
Revenue
-106.0
Net Income
-8.8M
EPS (Diluted)
$-36.24
Free Cash Flow
-8.1M
Total Assets
5.1M
Cash
4.7M
Profitability Ratios
Gross Margin
-5,270,936.8%
Operating Margin
8,277,781.1%
Net Margin
8,275,459.4%
ROE
-210.0%
ROA
-172.1%
FCF Margin
7,685,587.7%
Balance Sheet & Liquidity
Current Ratio
5.38x
Quick Ratio
5.38x
Debt/Equity
0.18x
Debt/Assets
78.4%
Interest Coverage
-797,677.09x
Long-term Debt
740.3K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:14:20.830736 |
Data as of: 2025-12-31 |
Powered by Claude AI